Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · see citing works

Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391 · see citing works

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial

Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301 · see citing works

The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs.

Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252 · see citing works

Human hallucinogen research: guidelines for safety

Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203 · see citing works

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 1× · see citing works

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · see citing works

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G., M., Garas, W., Paleos, C., Gorman, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01336-3 · Cited by 1,004 · see citing works

Pilot study of the 5-HT _2A R agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · see citing works

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905 · see citing works

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder

Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789 · see citing works

Serotonin and brain function: a tale of two receptors

Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739 · see citing works

Psychometric evaluation of the altered states of consciousness rating scale (OAV)

Studerus, E., Gamma, A., & Vollenweider, F. X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012412 · Cited by 683 · see citing works

The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study

Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674 · see citing works

X-ray structures and mechanism of the human serotonin transporter

Coleman, J. A., Green, E. M., & Gouaux, E. (2016) · Nature · doi:10.1038/nature17629 · Cited by 672 · see citing works

How do antidepressants work? New perspectives for refining future treatment approaches

Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30015-9 · Cited by 616 · see citing works

X-ray structure of dopamine transporter elucidates antidepressant mechanism

Penmatsa, A., Wang, K. H., & Gouaux, E. (2013) · Nature · doi:10.1038/nature12533 · Cited by 615 · see citing works

Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs

Bertilsson, L., Dahl, M., Dalén, P., & Al‐Shurbaji, A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01548.x · Cited by 579 · see citing works

The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.

Rudnick, G., & Wall, S. C. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1817 · Cited by 535 · see citing works

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506 · see citing works

Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study

Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451 · see citing works

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens

Rickli, A., Moning, O. D., Hoener, M. C., & Liechti, M. E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.05.001 · Cited by 379 · see citing works

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms

Barrett, F. S., Bradstreet, M. P., Leoutsakos, J.-M. S., Johnson, M. W., & Griffiths, R. R. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116678781 · Cited by 366 · see citing works

MDMA enhances emotional empathy and prosocial behavior

Hysek, C. M., Schmid, Y., Simmler, L. D., Domes, G., Heinrichs, M., Eisenegger, C., Preller, K. H., Quednow, B. B., & Liechti, M. E. (2014) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nst161 · Cited by 356 · see citing works

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354 · see citing works

Oxytocin-dependent reopening of a social reward learning critical period with MDMA

Nardou, R., Lewis, E. M., Rothhaas, R., Xu, R., Yang, A., Boyden, E., & Dölen, G. (2019) · Nature · doi:10.1038/s41586-019-1075-9 · Cited by 334 · see citing works

Comparison of acute lethal toxicity of commonly abused psychoactive substances

Gable, R. S. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00744.x · Cited by 322 · see citing works

Combination of Antidepressant Medications From Treatment Initiation for Major Depressive Disorder: A Double-Blind Randomized Study

Blier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020186 · Cited by 316 · see citing works

Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites

Battaglia, G., Brooks, B. P., Kulsakdinun, C., & Souza, E. B. D. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90056-8 · Cited by 301 · see citing works

Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study

Danforth, A. L., Grob, C. S., Struble, C., Feduccia, A. A., Walker, N., Jerome, L., Yazar-Klosinski, B., & Emerson, A. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5010-9 · Cited by 280 · see citing works

The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers

Roseman, L., Leech, R., Feilding, A., Nutt, D., & Carhart-Harris, R. L. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00204 · Cited by 274 · see citing works

Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates

Barrett, F. S., & Griffiths, R. R. (2017) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2017_474 · Cited by 273 · see citing works

RS-102221: A Novel High Affinity and Selective, 5-HT 2C Receptor Antagonist

Bonhaus, D. W., Weinhardt, K. K., Taylor, M., DeSouza, A., McNeeley, P. M., Szczepanski, K., Fontana, D., Trinh, J. V., Rocha, C., Dawson, M. W., et al. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00049-x · Cited by 253 · see citing works

Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase

White, T. L., Justice, A. J. H., & de Wit, H. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00818-3 · Cited by 248 · see citing works

Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram

Liechti, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00148-7 · Cited by 248 · see citing works

A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine

Carpenter, L. L., Yasmin, S., & Price, L. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01262-8 · Cited by 244 · see citing works

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA

Mithoefer, M. C., Grob, C. S., & Brewerton, T. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00576-3 · Cited by 239 · see citing works

The Background and Chemistry of MDMA

Shulgin, A. T. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472361 · Cited by 233 · see citing works

Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance

Dinis-Oliveira, R. J. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1278228 · Cited by 224 · cited 2× · see citing works

Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service–Related PTSD

Krystal, J. H., Rosenheck, R. A., Cramer, J. A., Vessicchio, J. C., Jones, K. M., Vertrees, J. E., Horney, R. A., Huang, G. D., Stock, C. J., & for the Veterans Affairs Cooperative Study No. 504 Group (2011) · JAMA · doi:10.1001/jama.2011.1080 · Cited by 220 · see citing works

MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?

Feduccia, A. A., & Mithoefer, M. C. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.003 · Cited by 217 · see citing works

Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy

Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., Monnette, C., Huidekoper, A., Strauss, N., & Wolfson, P. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1587556 · Cited by 217 · see citing works

A review of the acute subjective effects of MDMA/ecstasy

Baylen, C. A., & Rosenberg, H. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01423.x · Cited by 209 · see citing works

MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment

Verrico, C. D., Miller, G. M., & Madras, B. K. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0174-5 · Cited by 205 · see citing works

Clonidine in Cambodian Patients with Posttraumatic Stress Disorder

Kinzie, J. D., & LEUNG, P. (1989) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198909000-00005 · Cited by 198 · see citing works

Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults

Brown, R. T., Nicholas, C. R., Cozzi, N. V., Gassman, M. C., Cooper, K. M., Muller, D., Thomas, C. D., Hetzel, S. J., Henriquez, K. M., Ribaudo, A. S., et al. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0540-6 · Cited by 188 · see citing works

Psilocybin: from ancient magic to modern medicine

Nichols, D. E. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0311-8 · Cited by 187 · see citing works

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects

Becker, A. M., Holze, F., Grandinetti, T., Klaiber, A., Toedtli, V. E., Kolaczynska, K. E., Duthaler, U., Varghese, N., Eckert, A., Grünblatt, E., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2487 · Cited by 184 · see citing works

Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations

Grob, C. S., Poland, R. E., Chang, L., & Ernst, T. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00078-2 · Cited by 175 · see citing works

Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics

Farré, M., de la Torre, R., Mathúna, B. Ó., Roset, P. N., Peiró, A. M., Torrens, M., Ortuño, J., Pujadas, M., & Camı́, J. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1789-7 · Cited by 165 · see citing works

Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy

Wagner, M. T., Mithoefer, M. C., Mithoefer, A. T., MacAulay, R. K., Jerome, L., Yazar-Klosinski, B., & Doblin, R. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117711712 · Cited by 160 · see citing works

Chronic Administration of Serotonergic Antidepressants Attenuates the Subjective Effects of LSD in Humans

Bonson, K. R. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00145-4 · Cited by 157 · see citing works

Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study

Hysek, C. M., Simmler, L. D., Nicola, V. G., Vischer, N., Donzelli, M., Krähenbühl, S., Grouzmann, E., Huwyler, J., Hoener, M. C., & Liechti, M. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036476 · Cited by 157 · see citing works

X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine

Penmatsa, A., Wang, K. H., & Gouaux, E. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3029 · Cited by 157 · see citing works

Interaction of Amphetamines and Related Compounds at the Vesicular Monoamine Transporter

Partilla, J. S., Dempsey, A. G., Nagpal, A., Blough, B. E., Baumann, M. H., & Rothman, R. B. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103622 · Cited by 153 · see citing works

The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA (“Ecstasy”) in Humans

Hysek, C. M., Simmler, L. D., Ineichen, M., Grouzmann, E., Hoener, M. C., Brenneisen, R., Huwyler, J., & Liechti, M. E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.78 · Cited by 152 · see citing works

Acute psychological and physiological effects of MDMA (“Ecstasy”) after haloperidol pretreatment in healthy humans

Liechti, M. E., & Vollenweider, F. X. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00086-9 · Cited by 145 · see citing works

MDMA enhances “mind reading” of positive emotions and impairs “mind reading” of negative emotions

Hysek, C. M., Domes, G., & Liechti, M. E. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2645-9 · Cited by 144 · see citing works

The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3, 4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers

Liechti, M. E., & Vollenweider, F. X. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400313 · Cited by 144 · see citing works

Konstitutionsaufklärung und Synthese von Psilocybin

Hofmann, A. A., Frey, A., Ott, H., Petrzilka, T., & Troxler, F. (1958) · Cellular and Molecular Life Sciences · doi:10.1007/bf02160424 · Cited by 140 · see citing works

Serotonin toxicity of serotonergic psychedelics

Malcolm, B., & Thomas, K. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05876-x · Cited by 138 · see citing works

First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder

Sessa, B., Higbed, L., O’Brien, S., Durant, C. F., Sakal, C., Titheradge, D., Williams, T. M., Rose‐Morris, A., Brew-Girard, E., Burrows, S., et al. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121991792 · Cited by 136 · see citing works

Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination

Hysek, C. M., Simmler, L. D., Schillinger, N., Meyer, N., Schmid, Y., Donzelli, M., Grouzmann, E., & Liechti, M. E. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001132 · Cited by 126 · see citing works

Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine After Controlled Oral Administration to Young Adults

Kolbrich, E. A., Goodwin, R. S., Gorelick, D. A., Hayes, R. J., Stein, E. A., & Huestis, M. A. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181684fa0 · Cited by 124 · see citing works

3,4-Methylenedioxymethamphetamine (MDMA): Stereoselective interactions at brain 5-HT1 and 5-HT2 receptors

Lyon, R. A., Glennon, R., & Titeler, M. (1986) · Psychopharmacology · doi:10.1007/bf00178519 · Cited by 121 · see citing works

Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.

Pokorny, T., Preller, K., Kraehenmann, R., & Vollenweider, F. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.01.005 · Cited by 116 · see citing works

The early use of MDMA (‘Ecstasy') in Psychotherapy (1977–1985)

Passie, T. (2018) · Drug Science Policy and Law · doi:10.1177/2050324518767442 · Cited by 116 · see citing works

Death following ingestion of MDMA (ecstasy) and moclobemide

Vuori, E., Henry, J. A., Ojanperä, I. A., Nieminen, R., Savolainen, T., Wahlsten, P., & Jäntti, M. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00292.x · Cited by 114 · see citing works

The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans

Tancer, M., & Johanson, C.-E. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0576-z · Cited by 113 · see citing works

Pharmacological Interaction between 3,4-Methylenedioxymethamphetamine (Ecstasy) and Paroxetine: Pharmacological Effects and Pharmacokinetics

Farré, M., Abanades, S., Roset, P. N., Peiró, A. M., Torrens, M., O'Mathúna, B., Segura, M., & de la Torre, R. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.129056 · Cited by 113 · see citing works

Effects of MDMA (Ecstasy) on Prepulse Inhibition and Habituation of Startle in Humans after Pretreatment with Citalopram, Haloperidol, or Ketanserin

Liechti, M. E. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00199-8 · Cited by 102 · see citing works

Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting

English, B. A., Dortch, M. J., Ereshefsky, L., & Jhee, S. S. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0284-9 · Cited by 101 · see citing works

Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: a systematic review and meta-analysis of randomized controlled trials

Khachatryan, D., Groll, D., Booij, L., Sepehry, A. A., & Schütz, C. G. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.10.007 · Cited by 99 · see citing works

Serotonin-transporter mediated efflux: A pharmacological analysis of amphetamines and non-amphetamines

Hilber, B., Scholze, P., Dorostkar, M. M., Sandtner, W., Holy, M., Boehm, S., Singer, E. A., & Sitte, H. H. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.08.008 · Cited by 99 · see citing works

MDMA and PTSD treatment

Sessa, B. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2016.07.004 · Cited by 97 · see citing works

Who is ‘Molly’? MDMA adulterants by product name and the impact of harm-reduction services at raves

Saleemi, S., Pennybaker, S. J., Wooldridge, M., & Johnson, M. W. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117715596 · Cited by 95 · see citing works

Impact of psychostimulants on vesicular monoamine transporter function

Fleckenstein, A. E., & Hanson, G. R. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.077 · Cited by 93 · see citing works

Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases—A Systematic Review and Meta-Analysis of Clinical Trials

Vargas, A. S. O., Luís, Â., Barroso, M., Gallardo, E., & Pereira, L. (2020) · Biomedicines · doi:10.3390/biomedicines8090331 · Cited by 91 · see citing works

Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016

Leonard, J. B., Anderson, B. D., & Klein‐Schwartz, W. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118793086 · Cited by 89 · see citing works

Sex Differences in the Effects of MDMA (Ecstasy) on Plasma Copeptin in Healthy Subjects

Simmler, L. D., Hysek, C. M., & Liechti, M. E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1143 · Cited by 89 · see citing works

Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans

Hysek, C. M., Schmid, Y., Rickli, A., Simmler, L. D., Donzelli, M., Grouzmann, E., & Liechti, M. E. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01936.x · Cited by 82 · see citing works

Pill content, dose and resulting plasma concentrations of 3,4‐methylendioxymethamphetamine (MDMA) in recreational ‘ecstasy’ users

Morefield, K., Keane, M. J., FELGATE, P. D., White, J. M., & Irvine, R. J. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03399.x · Cited by 78 · see citing works

Qualitative Review of Serotonin Syndrome, Ecstasy (MDMA) and the use of Other Serotonergic Substances: Hierarchy of Risk

Silins, E., Copeland, J., & Dillon, P. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701449237 · Cited by 77 · see citing works

Psilocybin Mushroom ( Psilocybe semilanceata ) Intoxication with Myocardial Infarction

Borowiak, K. S., Ciechanowski, K., & Waloszczyk, P. (1998) · Journal of Toxicology Clinical Toxicology · doi:10.3109/15563659809162584 · Cited by 77 · see citing works

Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders

Thomas, K., Malcolm, B., & Lastra, D. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1320734 · Cited by 75 · see citing works

Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports

Nayak, S. M., Gukasyan, N., Barrett, F. S., Erowid, E., Erowid, F., & Griffiths, R. R. (2021) · Pharmacopsychiatry · doi:10.1055/a-1524-2794 · Cited by 74 · see citing works

VA/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder: Clinician Summary

(2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.16408 · Cited by 71 · see citing works

Glucuronidation of Psilocin and 4-Hydroxyindole by the Human UDP-Glucuronosyltransferases

Manevski, N., Kurkela, M. J., Höglund, C., Mauriala, T., Court, M. H., Yli‐Kauhaluoma, J. T., & Finel, M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031138 · Cited by 70 · see citing works

Effects of the α2-Adrenergic Agonist Clonidine on the Pharmacodynamics and Pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Healthy Volunteers

Hysek, C. M., Brugger, R., Simmler, L. D., Bruggisser, M., Donzelli, M., Grouzmann, E., Hoener, M. C., & Liechti, M. E. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.188425 · Cited by 69 · see citing works

The American Psychiatric Association Publishing Textbook of Psychopharmacology

Schatzberg, A., & Nemeroff, C. (2017) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615371624 · Cited by 69 · see citing works

The Consequences of 3,4-Methylenedioxymethamphetamine Induced CYP2D6 Inhibition in Humans

O’Mathúna, B., Farré, M., Rostami‐Hodjegan, A., Yang, J., Cuyàs, E., Torrens, M., Lozano, R. P., Abanades, S., Maluf, S., Tucker, G. T., et al. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318184ff6e · Cited by 69 · see citing works

Intimate insight: MDMA changes how people talk about significant others

Baggott, M. J., Kirkpatrick, M. G., Bedi, G., & de Wit, H. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581962 · Cited by 65 · see citing works

Contribution ???of ???Cytochrome??? P450??2D6??to??3,4-Methylenedioxymethamphetamine Disposition in Humans

Segura, M., Farr, M., Pichini, S., Peir, A. M., Roset, P. N., rez, A. R., Ortu�o, J., Pacifici, R., Zuccaro, P., Segura, J., et al. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544060-00006 · Cited by 65 · see citing works

The Variability of Ecstasy Tablets Composition in Brazil

Togni, L. R., Lanaro, R., Resende, R. R., & Costa, J. L. (2014) · Journal of Forensic Sciences · doi:10.1111/1556-4029.12584 · Cited by 64 · see citing works

Use of psilocybin (“mushrooms”) among US adults: 2015–2018

Yockey, R. A., & King, K. A. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2020.00159 · Cited by 64 · see citing works

β-Blockers, Cocaine, and the Unopposed α-Stimulation Phenomenon

Richards, J. R., Hollander, J. E., Ramoska, E. A., Fareed, F. N., Sand, I. C., Gómez, M. M. I., & Lange, R. A. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248416681644 · Cited by 61 · see citing works

Urinary MDMA, MDA, HMMA, and HMA Excretion Following Controlled MDMA Administration to Humans

Abraham, T. T., Barnes, A. J., Lowe, R. H., Kolbrich, E. A., Milman, G., Pirnay, S., Gorelick, D. A., Goodwin, R. S., & Huestis, M. A. (2009) · Journal of Analytical Toxicology · doi:10.1093/jat/33.8.439 · Cited by 59 · see citing works

Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex

Hysek, C. M., & Liechti, M. E. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2761-6 · Cited by 58 · see citing works

Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3,4-methylenedioxymethamphetamine ('ecstasy')

Bingham, C. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.10.2654 · Cited by 56 · see citing works

α1-Adrenergic Receptors Contribute to the Acute Effects of 3,4-Methylenedioxymethamphetamine in Humans

Hysek, C. M., Fink, A. E., Simmler, L. D., Donzelli, M., Grouzmann, E., & Liechti, M. E. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182979d32 · Cited by 56 · see citing works

Reinforcing Subjective Effects of (??) 3,4-Methylenedioxymethamphetamine (???Ecstasy???) May Be Separable from its Neurotoxic Actions

McCann, U. D., & Ricaurte, G. A. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199306000-00011 · Cited by 55 · see citing works

Comorbid Conditions Explain the Association Between Posttraumatic Stress Disorder and Incident Cardiovascular Disease

Scherrer, J. F., Salas, J., Cohen, B. E., Schnurr, P. P., Schneider, D., Chard, K. M., Tuerk, P. W., Friedman, M. J., Norman, S. B., van den Berk‐Clark, C., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011133 · Cited by 55 · see citing works

A Case of Mao Inhibitor/MDMA Interaction: Agony After Ecstasy

Smilkstein, M. J., Smolinske, S. C., & Rumack, B. H. (1987) · Journal of Toxicology Clinical Toxicology · doi:10.3109/15563658708992620 · Cited by 54 · see citing works

Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.

Fogg, C., Michaels, T. I., de la Salle, S., Jahn, Z. W., & Williams, M. T. (2021) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000490 · Cited by 54 · see citing works

Short- and long-term effects of MDMA (“ecstasy”) on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo

Bogen, I. L., Haug, K. H., Myhre, O., & Fonnum, F. (2003) · Neurochemistry International · doi:10.1016/s0197-0186(03)00027-5 · Cited by 54 · see citing works

CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals

Schmid, Y., Vizeli, P., Hysek, C. M., Prestin, K., zu Schwabedissen, H. E. M., & Liechti, M. E. (2016) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000231 · Cited by 53 · see citing works

Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies

Studerus, E., Vizeli, P., Harder, S., Ley, L., & Liechti, M. E. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121998322 · Cited by 53 · see citing works

Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA

Hasler, F., Studerus, E., Lindner, K., Ludewig, S., & Vollenweider, F. X. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094650 · Cited by 52 · see citing works

Ecstasy and the concomitant use of pharmaceuticals

Copeland, J., Dillon, P., & Gascoigne, M. B. (2005) · Addictive Behaviors · doi:10.1016/j.addbeh.2005.05.025 · Cited by 51 · see citing works

Interactions between Bupropion and 3,4-Methylenedioxymethamphetamine in Healthy Subjects

Schmid, Y., Rickli, A., Schaffner, A., Duthaler, U., Grouzmann, E., Hysek, C. M., & Liechti, M. E. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222356 · Cited by 51 · see citing works

Effects of a -blocker on the cardiovascular response to MDMA (Ecstasy)

Hysek, C. M., Vollenweider, F. X., & Liechti, M. E. (2010) · Emergency Medicine Journal · doi:10.1136/emj.2009.079905 · Cited by 50 · see citing works

Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects

Vizeli, P., Schmid, Y., Prestin, K., zu Schwabedissen, H. E. M., & Liechti, M. E. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.01.008 · Cited by 50 · see citing works

Serotonin toxicity involving MDMA (ecstasy) and moclobemide

Pilgrim, J. L., Gerostamoulos, D., Woodford, N. W. F., & Drummer, O. H. (2011) · Forensic Science International · doi:10.1016/j.forsciint.2011.04.008 · Cited by 45 · see citing works

Deaths related to MDMA (ecstasy/molly): Prevalence, root causes, and harm reduction interventions

Rigg, K. K., & Sharp, A. (2018) · Journal of Substance Use · doi:10.1080/14659891.2018.1436607 · Cited by 45 · see citing works

Posttraumatic Growth After MDMA‐Assisted Psychotherapy for Posttraumatic Stress Disorder

Gorman, I., Belser, A. B., Jerome, L., Hennigan, C., Shechet, B., Hamilton, S., Yazar‐Klosinski, B., Emerson, A., & Feduccia, A. A. (2020) · Journal of Traumatic Stress · doi:10.1002/jts.22479 · Cited by 44 · see citing works

MDMA: a social drug in a social context

Kirkpatrick, M. G., & de Wit, H. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3752-6 · Cited by 42 · see citing works

Paroxetine Inhibits Acute Effects of 3,4-Methylenedioxymethamphetamine on the Immune System in Humans

Pacifici, R., Pichini, S., Zuccaro, P., Farré, M., Segura, M., Ortuño, J., Carlo, S. D., Bacosi, A., Roset, P. N., Segura, J., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.061374 · Cited by 41 · see citing works

Olanzapine as the ideal “trip terminator”? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance‐related psychotic symptoms

Valeriani, G., Corazza, O., Bersani, F. S., Melcore, C., Metastasio, A., Bersani, G., & Schifano, F. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2431 · Cited by 41 · see citing works

Human hallucinogen interactions with drugs affecting serotonergic neurotransmission.

Strassman, R. J. (1992) · PubMed · Cited by 41 · see citing works

Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy

Oeri, H. E. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120920420 · Cited by 41 · see citing works

Variability in the 3,4-methylenedioxymethamphetamine content of 'ecstasy' tablets in the UK

Wood, D. M., Stribley, V., Dargan, P. I., Davies, S., Holt, D. W., & Ramsey, J. (2010) · Emergency Medicine Journal · doi:10.1136/emj.2010.092270 · Cited by 40 · see citing works

Survival After Massive Ecstasy Overdose

Ramcharan, S., Meenhorst, P. L., Otten, J., Koks, C. H. W., de Boer, D., Maes, R. A. A., & Beijnen, J. H. (1998) · Journal of Toxicology Clinical Toxicology · doi:10.3109/15563659809162623 · Cited by 40 · see citing works

Doxazosin Treatment for Posttraumatic Stress Disorder

Jong, J. D., Wauben, P., Huijbrechts, I. P. A. M., Oolders, H., & Haffmans, J. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c827ae · Cited by 37 · see citing works

MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens

Müller, F., Holze, F., Dolder, P. C., Ley, L., Vizeli, P., Soltermann, A., Liechti, M. E., & Borgwardt, S. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00906-2 · Cited by 37 · see citing works

What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review

Castro Santos, H., & Gama Marques, J. (2021) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000128 · Cited by 37 · see citing works

MDMA interactions with pharmaceuticals and drugs of abuse

Papaseit, E., Pérez‐Mañá, C., Torrens, M., Farré, A., Poyatos, L., Hladun, O., Sanvisens, A., Muga, R., & Farré, M. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1749262 · Cited by 36 · see citing works

Memory and mood during MDMA intoxication, with and without memantine pretreatment

Perna, E. B. D. S. F., Theunissen, E. L., Kuypers, K. P. C., Heckman, P. R. A., de la Torre, R., Farré, M., & Ramaekers, J. G. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.03.008 · Cited by 34 · see citing works

The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors

Liu, Y., She, M., Wu, Z., & Dai, R. (2010) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2010.518965 · Cited by 34 · see citing works

How do serotonergic psychedelics treat depression: The potential role of neuroplasticity

Artin, H., Zisook, S., & Ramanathan, D. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i6.201 · Cited by 33 · see citing works

Ecstasy use and serotonin syndrome: a neglected danger to adolescents and young adults prescribed selective serotonin reuptake inhibitors

Dobry, Y., Rice, T., & Sher, L. (2013) · International Journal of Adolescent Medicine and Health · doi:10.1515/ijamh-2013-0052 · Cited by 31 · see citing works

Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database

Cohen, I. V., Makunts, T., Abagyan, R. A., & Thomas, K. L. H. (2021) · Scientific Reports · doi:10.1038/s41598-021-85389-x · Cited by 31 · see citing works

Stress-Induced In Vivo Recruitment of Human Cytotoxic Natural Killer Cells Favors Subsets with Distinct Receptor Profiles and Associates with Increased Epinephrine Levels

Bigler, M. B., Egli, S. B., Hysek, C. M., Höenger, G., Schmied, L., Baldin, F. S., Marquardsen, F. A., Recher, M., Liechti, M. E., Hess, C., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145635 · Cited by 30 · see citing works

Effects of "Ecstasy" Blocked by Serotonin Reuptake Inhibitors

Stein, D. J., & Rink, J. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0711a · Cited by 24 · see citing works

Acute, transient urinary retention from combined ecstasy and methamphetamine use

Delgado, J. H., Caruso, M. J., Waksman, J. C., Honigman, B., & Stillman, D. (2004) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2003.05.007 · Cited by 21 · see citing works

17β-Estradiol up-regulates UDP-glucuronosyltransferase 1A9 expression via estrogen receptor α

Cho, S., Ning, M., Zhang, Y., Rubin, L. H., & Jeong, H. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.04.005 · Cited by 20 · see citing works

Possible interaction between an MAOI and "ecstasy"

Kaskey, G. B. (1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.3.411a · Cited by 20 · see citing works

Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans

Steuer, A. E., Schmidhauser, C., Tingelhoff, E. H., Schmid, Y., Rickli, A., Kræmer, T., & Liechti, M. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150955 · Cited by 18 · see citing works

Surviving life-threatening MDMA (3,4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir (RTV)

Papaseit, E., Vázquez, A., Pérez‐Mañá, C., Pujadas, M., de la Torre, R., Farré, M., & Nolla, J. (2012) · Intensive Care Medicine · doi:10.1007/s00134-012-2537-9 · Cited by 16 · see citing works

Topiramate prevents ecstasy consumption: a case report

Akhondzadeh, S., & Hampa, A. D. (2005) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2005.00355.x · Cited by 14 · see citing works

Interaction of serotonin reuptake inhibitor and 3,4-methylenedioxymethamphetamine?

Lauerma, H., Wuorela, M., & Halme, M. (1998) · PubMed · Cited by 12 · see citing works

Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reportsPreprint

Nayak, S. M., Gukasyan, N., Barrett, F. S., et al. (2021) · doi:10.31234/osf.io/r726d · Cited by 10 · see citing works

Correspondence

(1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00021-3 · Cited by 9 · see citing works

�ber den Einflu� von Ergotamin auf die LSD-?Psychose? beim Menschen

Matussek, N., & Halbach, A. (1964) · Psychopharmacology · doi:10.1007/bf00413052 · Cited by 8 · see citing works

Sean C. Sweetman (Ed.): Martindale: The Complete Drug Reference

Scriba, G. K. E. (2011) · Chromatographia · doi:10.1007/s10337-011-2101-8 · Cited by 4 · see citing works

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey

Nayak, S. M., Jackson, H., Sepeda, N. D., Mathai, D. S., So, S., Yaffe, A., Zaki, H., Brasher, T. J., Lowe, M. X., Jolly, D. R. P., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1199642 · Cited by 93 · see citing works

Drug–drug interactions involving classic psychedelics: A systematic review

Halman, A., Kong, G., Sarris, J. J., & Perkins, D. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231211219 · Cited by 74 · see citing works

Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use

Gukasyan, N., Griffiths, R. R., Yaden, D. B., Antoine, D. G., & Nayak, S. M. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231179910 · Cited by 67 · see citing works

Cardiovascular safety of psychedelic medicine: current status and future directions

Wsół, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00539-4 · Cited by 60 · see citing works

The need for establishing best practices and gold standards in psychedelic medicine

Feduccia, A. A., Agin-Liebes, G., Price, C. M., Grinsell, N., Paradise, S., & Rabin, D. M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.083 · Cited by 43 · see citing works

Neuroimaging in psychedelic drug development: past, present, and future

Wall, M. B., Harding, R., Zafar, R. R., Rabiner, E. A., Nutt, D., & Erritzøe, D. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02271-0 · Cited by 41 · see citing works

A journey with psychedelic mushrooms: From historical relevance to biology, cultivation, medicinal uses, biotechnology, and beyond

Pepe, M., Hesami, M., de la Cerda, K. A., Perreault, M. L., Hsiang, T., & Jones, A. M. P. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108247 · Cited by 36 · see citing works

Exploring mechanisms of psychedelic action using neuroimaging

Erritzøe, D., Timmermann, C., Godfrey, K. E. M., Castro-Rodrigues, P., Peill, J. M., Carhart-Harris, R. L., Nutt, D., & Wall, M. B. (2024) · Nature Mental Health · doi:10.1038/s44220-023-00172-3 · Cited by 33 · see citing works

Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research

McIntyre, R. S., Kwan, A. T. H., Mansur, R. B., Oliveira-Maia, A. J., Teopiz, K. M., Maletic, V., Suppes, T. M., Stahl, S. M., & Rosenblat, J. D. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230902 · Cited by 32 · see citing works

Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers

Boehnke, K. F., Cox, K., Weston, C. L., Herberholz, M., Glynos, N. G., Kolbman, N., Fields, C. W., Barron, J., & Kruger, D. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1224551 · Cited by 28 · see citing works

Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia

Nadeem, Z., Parker, S., McGovern, H. T., & Oestreich, L. (2024) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674241261779 · Cited by 20 · see citing works

The efficacy and safety of MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review and meta-analysis from randomized controlled trials

Yang, J., Wang, N., Luo, W., & Gao, J. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116043 · Cited by 19 · see citing works

Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022

Jing, X., Hoeh, N. R., & Menkes, D. B. (2023) · Palliative & Supportive Care · doi:10.1017/s147895152300069x · Cited by 17 · see citing works

The development of psilocybin therapy for treatment-resistant depression: an update

Borissova, A., & Rucker, J. (2023) · BJPsych Bulletin · doi:10.1192/bjb.2023.25 · Cited by 18 · see citing works

Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-Methylenedioxymethamphetamine–Assisted Therapy for Posttraumatic Stress Disorder

Price, C. M., Feduccia, A. A., & DeBonis, K. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001595 · Cited by 17 · see citing works

MDMA-assisted psychotherapy for borderline personality disorder

Traynor, J. M., Roberts, D. E., Ross, S., Zeifman, R., & Choi-Kain, L. (2022) · Focus · doi:10.1176/appi.focus.20220056 · Cited by 15 · see citing works

Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design

Muthukumaraswamy, S. D., Baggott, M. J., Schenberg, E. E., Repantis, D., Wolff, M., Forsyth, A., & Noorani, T. N. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251381074 · Cited by 16 · see citing works

Exploring Psilocybe cubensis Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps

Kurzbaum, E., Páleníček, T., Sharchaton, A., Azerrad, S., & Dekel, Y. (2025) · Journal of Fungi · doi:10.3390/jof11020099 · Cited by 15 · see citing works

Expert recommendations for Germany’s integration of psychedelic-assisted therapy

Rosal, S. P., Torre, J. T. L., Birnkammer, S., Chernoloz, O., Williams, M. T., & Faber, S. C. (2024) · BMC Medical Education · doi:10.1186/s12909-024-06141-3 · Cited by 13 · see citing works

Less is more? A review of psilocybin microdosing

Savides, I. A., & Outhoff, K. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241278769 · Cited by 12 · see citing works

Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon

Bellman, V. (2024) · Cancers · doi:10.3390/cancers16091702 · Cited by 8 · see citing works

Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer

Petridis, P. D., Grinband, J., Agin-Liebes, G., Kinslow, C. J., Zeifman, R. J., Bogenschutz, M. P., Griffiths, R. R., & Ross, S. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00331-0 · Cited by 10 · see citing works

The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges

Scala, M., Fabbri, C., Fusar-Poli, P., Di Lorenzo, G., Ferrara, M., Amerio, A., Fusar-Poli, L., Pichiecchio, A., Asteggiano, C., Menchetti, M., et al. (2024) · CNS Spectrums · doi:10.1017/s1092852924002268 · Cited by 9 · see citing works

Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol

Butler, M., Bird, C., Maggio, C., Durden, A., Modlin, N. L., Campbell‐Coker, K., Edwards, M. J., Pick, S., Millman, L. S. M., Lowery, E., et al. (2024) · Wellcome Open Research · doi:10.12688/wellcomeopenres.22543.1 · Cited by 8 · see citing works

Psilocybin and chronic neuropathic pain: a systematic review

Jevotovsky, D. S., Chopra, H., Pak, D., Durbhakula, S., Shustorovich, A., Juneja, T., Broachwala, M. Y., AlFarra, T., Silver, C., Kreitzer, G., et al. (2024) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2024-105532 · Cited by 9 · see citing works

Psychedelic medicine: mechanisms, evidence, and translation to practice

Jacobs, E., Zahid, Z., Hinkle, J. T., Nayak, S. M., & Yaden, D. B. (2026) · BMJ · doi:10.1136/bmj-2024-081723 · Cited by 9 · see citing works

Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper

Destoop, M., Mohr, P., Butlen‐Ducuing, F., Kéri, P., Samochowiec, J., Picker, L. D., Fiorillo, A., Kuypers, K. P. C., & Dom, G. (2025) · European Psychiatry · doi:10.1192/j.eurpsy.2024.1806 · Cited by 8 · see citing works

Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers

Nadeem, Z., Parker, S., McGovern, H. T., Sebben, B., & Oestreich, L. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674251346679 · Cited by 8 · see citing works

Concomitant use of antidepressants and classic psychedelics: A scoping review

Tap, S. C., Thomas, K. L. H., Páleníček, T., Stenbæk, D. S., Oliveira-Maia, A. J., van Dalfsen, J. H., & Schoevers, R. A. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251368360 · Cited by 10 · see citing works

Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential

Raj, P., Rauniyar, S. P., & Sapkale, B. (2023) · Cureus · doi:10.7759/cureus.48719 · Cited by 9 · see citing works

Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system

Makunts, T., Dahill, D., Jerome, L., de Boer, A., & Abagyan, R. A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1149766 · Cited by 7 · see citing works

Psychedelic Trips: Travel Within the United States to Use Psychedelic Drugs After Legalization

Black, J. C., Rockhill, K. M., Fox, E. J., Jewell, J. S., Dart, R. C., & Monte, A. A. (2025) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2025.05.016 · Cited by 6 · see citing works

Building standards of psychedelic care: Qualitative examination of expert perspectives on safety, inclusion, and accountability

Chwyl, C., Wilson‐Poe, A. R., Hoffman, K. A., Bazinet, A. D., Pertl, K., Luoma, J. B., Jarlais, D. C. D., Bielavitz, S., & Korthuis, P. T. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104938 · Cited by 6 · see citing works

Long‐COVID symptoms improved after MDMA and psilocybin therapy: A case report

Chopra, H., Furnish, T. J., Verduzco‐Gutierrez, M., Jevotovsky, D. S., & Castellanos, J. P. (2024) · Clinical Case Reports · doi:10.1002/ccr3.8791 · Cited by 6 · see citing works

Psilocybine services in Oregon: a call for awareness among clinical toxicologists

Sudakin, D. L. (2023) · Clinical Toxicology · doi:10.1080/15563650.2023.2182664 · Cited by 6 · see citing works

Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia

Sapienza, J., Spangaro, M., Comai, S., Sabé, M., Torre, J. T. L., Buonarroti, M., Cavallaro, R., & Bosia, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188949 · Cited by 4 · see citing works

Caffeine, nicotine, cannabis, and psilocybin: Pharmacology, toxicology, and potential therapeutic uses of four naturally occurring psychoactive substances

Christen, S. E., Bekka, E., Schmid, Y., Benowitz, N. L., & Liakoni, E. (2025) · Swiss Medical Weekly · doi:10.57187/s.4346 · Cited by 4 · see citing works

Psilocybin Use in the Autism Spectrum Disorder: A Scoping Review

Moreno‐Chaparro, J., Castañeda-Millán, G., & Eslava-Schmalbach, J. H. (2025) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000653 · Cited by 4 · see citing works

Psilocybin-assisted psychotherapy in adults with depression - A literature review.

Dorczok, M. C., Mittmann, G., Ettl, T., & Steiner-Hofbauer, V. (2025) · Progress in Neuro-psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111508 · Cited by 3 · see citing works

Neuroimaging and the Investigation of Drug-Drug Interactions Involving Psychedelics

Wall, M. B., Harding, R., Ertl, N., Barba, T., Zafar, R. R., Sweeney, M., Nutt, D., Rabiner, E. A., & Erritzøe, D. (2024) · Neuroscience Insights · doi:10.1177/26331055241286518 · Cited by 3 · see citing works

Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report

Do, A., Michaud, V., Stephan, J.-F., Moreau, M., Benoît, É., Berubé, F.-A., Serres, A. B.-D., Taillefer, A., & Vincent, P. D. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1394962 · Cited by 3 · see citing works

Toxicology and Pharmacological Interactions of Classic Psychedelics

Thomas, K. L. H. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_508 · Cited by 3 · see citing works

MDMA and Their Analogs as Therapeutics for Mental Disorder and Response Predictor

Kargbo, R. B. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00389 · Cited by 3 · see citing works

Ketamine-assisted group psychotherapy integrating cognitive processing therapy to address identity-based trauma: a pilot study

Sevelius, J. M., Golden, R. L., Stott, B. L., Kozicz, N. O., Mukerjee, R., Cluesman, S. R., Jones, T., & Cornelius, T. M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1727487 · Cited by 2 · see citing works

Self-perception and self-recognition while looking in the mirror on psilocybin

Elias, S., Spivak, S., Alverez, A., Olivares, A. G., Ferrol, M., & Keenan, J. P. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00251 · Cited by 2 · see citing works

Drug–Drug Interactions in Psychopharmacology

Alpert, J. E., & Mischoulon, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11972-9.00014-4 · Cited by 2 · see citing works

Is there a place for psychedelics in sports practice?

Portes, M. A. M., Werle, I., & Bertoglio, L. J. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.13 · Cited by 2 · see citing works

Drug–Drug Interactions in Psychopharmacology

Alpert, J. E., & Mischoulon, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11844-9.00056-4 · Cited by 2 · see citing works

Psilocybin as a psychophysical adaptogen in chronic pain rehabilitation

Cherup, N. P., & Finan, P. H. (2025) · Journal of Pain · doi:10.1016/j.jpain.2025.105507 · Cited by 2 · see citing works

Psilocybin use in bipolar disorder: A comprehensive review

Do, A., Cloutier, L., Hébert‐Tremblay, L., & Thauvin, C. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120485 · Cited by 1 · see citing works

Integrating psychedelic-assisted psychotherapy into addiction care in the Czech Republic: Clinical evidence, safety, and regulatory developments

Postránecká, Z., Lucký, M., Mravčík, V., & Páleníček, T. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00514 · Cited by 1 · see citing works

Level of preparedness to use psilocybin among individuals seeking psychedelic risk reduction: a retrospective study of a pilot psychiatric consultation service

Harrison, H. V., Gaillard, M., Cook, R. R., Sarparast, A., & Levander, X. A. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1921031 · Cited by 1 · see citing works

Psychedelic-Assisted Therapy and Meditative Experience as Factors of Personal Change

Omelchenko, N., & Kurapov, A. (2023) · Bulletin of Taras Shevchenko National University of Kyiv. Psychology · doi:10.17721/bpsy.2023.1(17).8

Pharmacists and psychedelic medicine

Thomas, K. L. H. (2023) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1876 · Cited by 1 · see citing works

Resurrecting Ancestral Familial Health: A Role for Psilocybin?

Glowiak, A. (2024) · The Family Journal · doi:10.1177/10664807241269505 · Cited by 1 · see citing works

Psychedelic therapy for body dysmorphic disorder

Johnson, S., & Letheby, C. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00200 · Cited by 1 · see citing works

MDMA, Internal Family Systems therapy, and the Minnesota model in the resolution of C-PTSD-induced alcohol and diazepam addiction—A retrospective case studyPreprint

Turkia, M. (2023) · doi:10.31234/osf.io/fpb83 · Cited by 1 · see citing works

Psychedelics: Old trips, new destinations in psychopharmacology research

de Wit, H., & D’Souza, D. C. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06152-2

Understanding psychedelic 'mystical experience'—A case examplePreprint

Turkia, M. (2023) · doi:10.31234/osf.io/dh92g

The Future for Psychedelic Agents in the Treatment of Posttraumatic Stress Disorder

Haycraft, A. L. (2023) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2023.104586

Klassieke psychedelica: veiligheid, neveneffecten en medicatie-interacties

Geleyn, E., Kuypers, K. P. C., Seynaeve, M., & Lemmens, G. M. D. (2023) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.79.23.049

Evidencias y perspectivas del potencial antidepresivo del “alcaloide mágico” psilocibina: una revisión narrativa

Toledo, M. M. V. (2023) · Cultura y Droga · doi:10.17151/culdr.2023.28.35.5

Open MDMA: An Open Source Framework and Practical Guide for the Therapeutic use of MDMAPreprint

Groeneveld, M., & Harper, T. (2024) · doi:10.31234/osf.io/aps5g

How Does Psilocybin Therapy Work? an Exploration of Experiential Avoidance as a Putative Mechanism of Change

Zeifman, R. J. (2024) · doi:10.32920/26052859.v1 · Cited by 1 · see citing works

Interactome: A Platform for Comprehensive Drug-Drug Interaction Analysis

Sivakumar, A., Bhanot, S., Srinidhi, M., & Milan, K. A. (2024) · International Conference on Computing, Communication and Networking Technologies (ICCCNT) · doi:10.1109/icccnt61001.2024.10725436

Psilocybe cubensis: potencial neuropsicofarmacéutico de la psilocibina y psilocina

Barrientos-Alfaro, F. C., Herrera-Rojas, V., Montero-Quesada, M., Morales, J. J. P., & Sanabria-Brenes, M. (2024) · Revista Tecnología en Marcha · doi:10.18845/tm.v37i9.7618

Mushroom Neurotoxicity

White, J., Ward, A., & Rowland, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00271-2

Open MDMA: An Evidence-Based Synthesis, Theory, and Manual for MDMA Therapy Based on Memory Reconsolidation, Complex Systems, and the Defense CascadePreprint

Groeneveld, M., & Harper, T. (2024) · doi:10.31234/osf.io/aps5g_v1

Open MDMA: An Evidence-Based Mixed-Methods Review, Theoretical Framework, and Manual for MDMA TherapyPreprint

Groeneveld, M., & Harper, T. (2025) · doi:10.31234/osf.io/aps5g_v3

Psychedelics reduce fear by targeting immune cells that modulate brain cells

Chen, Y., & Colonna, M. (2025) · Nature · doi:10.1038/d41586-025-01133-9

Exploring psychedelic experiences among people who regularly use methamphetamine: Findings from an international survey

Bahceci, D., Siefried, K. J., Steele, M., Harrod, M., Bell, G., Barratt, M. J., Nicholas, C. R. N., Rodgers, A., Hendricks, P. S., Stauffer, C. S., et al. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112699

MDMA

Waldman, E. D., Romanko, M., Skellie, M., & Bates, M. (2025) · doi:10.1093/med/9780197760864.003.0003

Psilocybin

Humphreys, J., Lukas, L. A., Beaussant, Y., Fischer, S. M., Araujo, T. S., Spence, D., Harris, J. P., Anderson, B. T., & Grob, C. S. (2025) · doi:10.1093/med/9780197760864.003.0002

Is there mush-room to improve the environmental sustainability of psilocybin production?

Lanham, L., McTaggart, A. R., & Falconer, J. R. (2025) · Journal of CO2 Utilization · doi:10.1016/j.jcou.2025.103137

Australia’s psychedelic experiment: reflections from a psychiatrist clinical researcher

Bayes, A. J. (2025) · Australasian Psychiatry · doi:10.1177/10398562251347890

Open MDMA: An Evidence-Based Synthesis, Theory, and Manual for MDMA Therapy Based on Predictive Processing, Complex Systems, and the Defense CascadePreprint

Groeneveld, M., & Harper, T. (2025) · doi:10.31234/osf.io/aps5g_v4

Ethical challenges in the therapeutic application of classical psychedelics for pediatric health conditions: A comprehensive review

Vlotinou, P., Christodoulou, K., Tsiakiri, A., Christidi, F., & Serdari, A. (2025) · Brazilian Journal of Science · doi:10.14295/bjs.v4i10.785

PHARMACOLOGICAL TREATMENT OF PTSD WITH PSYCHEDELICS: A FUTURE OUTLOOK

Gorski, M., Januszkiewicz, A., Januszkiewicz, W., Machulski, W., Ciarkowska, M., Makulski, J. K., Franczyk, K., Swierk, K., Podkościelny, D., & Gierasimiuk, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4392

Trip killers: Addressing a critical knowledge gap in psychedelic research

O’Mahony, B. W., Harrington, C., Harkin, A., & Lally, N. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261431056

MDMA-assisted therapy for PTSD and Substance Use Disorders: A Scoping Review of Feasibility and Future Directions

Meijer, T. L., van Opdorp, A., & Markus, W. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100014

The impact of antidepressant use on MDMA fatalities: A matched case-control study using a post-mortem database

Rock, K. L., Rees, P., Morgan, D., & Copeland, C. S. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261436573

Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians

Boehnke, K. F., Pouyan, N., & Aday, J. S. (2026) · Drugs · doi:10.1007/s40265-026-02339-5 · Cited by 1 · see citing works

Questions on Medicines, Alcohol, and Illicit Drug Interactions in the Finnish AddictionLink Online Service: A Descriptive Analysis

Vaarankorpi, M., Valkonen, V., & Karttunen, N. M. (2026) · Nordic Studies on Alcohol and Drugs · doi:10.1177/14550725261463002

Cardiovascular safety of psilocybin in psychiatric practice: a narrative review

Szarpak, Ł., Pruc, M., Świeczkowski, D., Rybczynski, B., Pięta, A., & Cubała, W. J. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04151-2

Prevalence of Potential Contraindications and Risk Factors Relevant to MDMA-Assisted Therapy Among U.S. Veterans with Posttraumatic Stress Disorder

Hwang, C. S., Cameron, D. C., O’Neill, A. C., Morasco, B. J., Dobscha, S. K., Korthuis, P. T., & Stauffer, C. S. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2710059

Drug, set, and setting in overdose events among young adults

Kaskela, T., Rönkä, S., & Helfer, A. (2026) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2026.2725699

Multidimensional clinical benefits of cinnamon leaf oil inhalation in primary and metastatic brain tumor patients during winter: A randomized controlled trial

Zhang, Q., Zhao, Y., Man, X., & Yan, D. (2026) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2026.103449

Drug–drug interactions involving classic psychedelics: A systematic review

Halman, A., Kong, G., Sarris, J. J., & Perkins, D. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231211219 · Cited by 74 · see citing works

Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders

Rhee, T. G., Davoudian, P. A., Sanacora, G., & Wilkinson, S. T. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103818 · Cited by 21 · see citing works

Do psilocybin or methylenedioxymethamphetamine (MDMA) improve mental, behavioural or developmental disorders either as stand - alone treatments or in combination with psychotherapy?Preprint

Kisely, S. R. (2021) · doi:10.17605/osf.io/7z4dp

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA

Mithoefer, M. C., Grob, C. S., & Brewerton, T. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00576-3 · Cited by 239 · see citing works

Neuroimaging and the Investigation of Drug-Drug Interactions Involving Psychedelics

Wall, M. B., Harding, R., Ertl, N., Barba, T., Zafar, R. R., Sweeney, M., Nutt, D., Rabiner, E. A., & Erritzøe, D. (2024) · Neuroscience Insights · doi:10.1177/26331055241286518 · Cited by 3 · see citing works